NCT07203053RecruitingPhase 2
A clinical study to investigate the efficacy of tarlatamab in people with extensive-stage small cell lung cancer (ES-SCLC) whose cancer has progressed during or after prior treatment and who have a limited health status.
ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Oct 2026
Brief summary (registry, in English)
The primary objective of the trial is to assess the clinical efficacy of tarlatamab in terms of 12-month overall survival (OS) rate in patients with ES-SCLC and ECOG PS 2 who have previously received one line of platinum-etoposide doublet chemotherapy with an immune-checkpoint inhibitor and whose disease has progressed.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 18 Dec 2025
- Start date
- 21 May 2026
- Lead sponsor
- ETOP IBCSG Partners Foundation
- Diseases
- Lung cancer
- NCT number
- NCT07203053
- EU CT number
- 2025-522288-13-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- 13 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history of immune-related recurrent pneumonitis (grade ≥2)) or severe immune-mediated adverse events
Other illness
- Diagnosis or evidence of leptomeningeal disease or spinal cord compression
- Evidence of interstitial lung disease or active, non-infectious pneumonitis
- Active autoimmune disease
- History of solid organ transplantation
- Presence or history of an uncontrolled viral infection
- History of other malignancy within the past 2 years
Other
- Symptomatic CNS metastases
Who the study is looking for
- Histologically or cytologically confirmed ES-SCLC
- Previous treatment with only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition for SCLC
- Progressive disease on or after the first-line treatment for SCLC
- ECOG Performance Status 2
- Age ≥18 years
- Adequate organ function
- Negative pregnancy test for female participants of childbearing potential
- Written Informed Consent signed before any trial-related intervention
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital General Universitario Dr. Balmis Coordinator of this site? Confirm its status | Alicante | Spain | Recruiting |
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Hospital de la Santa Creu i Sant Pau Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| ICO l'Hospitalet - Hospital Duran i Reynals Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Hospital Universitario Puerta de Hierro de Majadahonda Coordinator of this site? Confirm its status | Majadahonda | Spain | Recruiting |
| Centre Hospitalier Universitaire D'Angers Coordinator of this site? Confirm its status | Angers | France | Recruiting |
| Institut Bergonie Coordinator of this site? Confirm its status | Bordeaux | France | Recruiting |
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
| Centre Hospitalier Regional De Marseille Coordinator of this site? Confirm its status | Marseille | France | Recruiting |
| Henry Dunant Hospital Center Coordinator of this site? Confirm its status | Athens | Greece | Recruiting |
| Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l Coordinator of this site? Confirm its status | Meldola | Italy | Recruiting |
| Azienda Ospedaliera di Perugia Coordinator of this site? Confirm its status | Perugia | Italy | Recruiting |
| Irccs Istituto Nazionale Tumori Regina Elena Coordinator of this site? Confirm its status | Rome | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.